OpGen’s stock (NASDAQ:OPGN) skyrockets due to COVID-19 Connection
OpGen shares are up 101% after Monday in reaction to an announcement regarding a COVID-19 test kit from German molecular diagnostics company Curetis, which OpGen has agreed to merge with. OpGen is trading even higher after hours due to the news as it shows much profitability in OpGen future. Curetis has begun offering a CE-IVD-certified real-time PCR test kit for SARS-CoV-2, the virus causing COVID-19.
The test kit, developed and manufactured by Curetis’ Chinese strategic partner BGI, was cleared by the Chinese authorities in January. It was CE-IVD certified on Feb. 28. The CE certification indicates that the product is in conformity with health, safety and environmental protection standards for products sold in the European Economic Area. The test will be available to European labs through Curetis network.
March 16, 2020